Singapore, Nov. 11 -- Hong Kong-based Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has announced a research collaboration with Eli Lilly that the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.

Insilico will utilise its validated Pharma.AI platform and deep drug discovery expertise to generate, design, and optimize candidate compounds against targets defined under the agreement. Insilico is eligible to receive over $100 million including an upfront, milestone payments, and tiered royalties on net sales upon commercialization of any resulting drug produc...